Quick Answer
Acurx Pharmaceuticals, Inc. reported Diluted EPS of $5.32 per share (loss) for fiscal year 2025.
Acurx Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.32 | +69.5% |
| 2024 | -$17.45 | -1417.4% |
| 2023 | -$1.15 | -2.7% |
| 2022 | -$1.12 | +24.8% |
| 2021 | -$1.49 | -101.4% |
| 2020 | -$0.74 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.23 | +64.3% | +34.9% |
| June 30, 2025 | -$1.89 | +63.7% | -1618.2% |
| March 31, 2025 | -$0.11 | +60.7% | +96.8% |
| September 30, 2024 | -$3.45 | -1337.5% | +33.8% |
| June 30, 2024 | -$5.21 | -1760.7% | -1760.7% |
| March 31, 2024 | -$0.28 | -12.0% | -16.7% |
| September 30, 2023 | -$0.24 | +25.0% | +14.3% |
| June 30, 2023 | -$0.28 | -7.7% | -12.0% |
- Acurx Pharmaceuticals, Inc. showed an increase of +69.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Acurx Pharmaceuticals, Inc.’s diluted eps has declined by 618.9% (from $0.74 per share (loss) to $5.32 per share (loss)).
- The most recent figure is from Acurx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: